Product Description
Mechanisms of Action: Voltage-Gated Chlorine Channel Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mallinckrodt
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Osteoarthritis|Arthritis, Rheumatoid|Duodenal Ulcer|Hypertension, Portal|Stomatitis|Mucositis|Head and Neck Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02542215 |
SCMP-8811-202 | P2 |
Terminated |
Stomatitis|Head and Neck Cancer|Mucositis |
2016-07-01 |
2019-11-23 |
Primary Endpoints|Treatments |
|
NCT00597818 |
SU0621 | P2 |
Completed |
Arthritis, Rheumatoid|Osteoarthritis|Duodenal Ulcer |
2009-04-01 |
2019-12-29 |
||
NCT00737594 |
SPH0721 | P2 |
Terminated |
Hypertension, Portal |
2009-02-01 |
2019-11-23 |
Primary Endpoints|Treatments |
|
JapicCTI-152763 |
JapicCTI-152763 | P2 |
Completed |
Unknown |
None |
Recent News Events
Date |
Type |
Title |
|---|